New hemophilia drugs aim to simplify treatment

Published March 7, 2014

New hemophilia drugs aim to simplify treatment
The U.S. Food and Drug Administration is due to decide by mid-year whether to approve Alprolix, a new long-lasting hemophilia B clotting factor from Biogen Idec and partner Swedish Orphan Biovitrum. … to the hemophilia market decide to price their …
Read more on Reuters

FEATURE-New hemophilia drugs aim to simplify treatment
LOS ANGELES, March 7 (Reuters) – For 33-year-old video editor and hemophilia patient Travis Roop, being able to get life-saving infusions of a blood clotting agent every two weeks, instead of rushing to treat a bleeding episode, meant he could jog for …
Read more on Reuters

What It's Like on the Autism Spectrum
I kept my promise. I let my career stagnate; I researched mainstream and alternative treatments; found therapists and doctors; applied for special education; convinced insurance companies to cover him; got up night after night when he didn't sleep …
Read more on The Atlantic

More Drug Treatment Centers With No Insurance Information…